Selpercatinib side effects: what 357 FDA adverse event reports show

Selpercatinib · 30 reaction terms · 633 drug–reaction co-reports · data 2026-09-14

Drug class

No validated FDA label found

Who reports

357 reports · 96% serious · 47 with death outcome · 53% female

openFDA FAERS counts, all years, deduplication not applied

Used for

—

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 21 strongest signals

Reporting / coding artifact 4Lab value / disease marker 2No label text to screen 15

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 9 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Hepatotoxicity (liver damage)	34	24.4 17.5–34.0ROR 25.0 · χ² 738 / p 7e-163	24.0 EB05 18.0 · IC025 +3.6 3/3 methods agree	No label text to screen	–	no trial data cached
Hepatic cytolysis	17	22.1 13.8–35.4ROR 22.4 · χ² 321 / p 4e-72	21.5 EB05 14.1 · IC025 +3.0 3/3 methods agree	No label text to screen	–	no trial data cached
Liver function test increased	29	21.6 15.1–31.0ROR 22.1 · χ² 549 / p 1e-121	21.3 EB05 15.5 · IC025 +3.4 3/3 methods agree	No label text to screen	–	no trial data cached
Hepatic function abnormal	48	20.6 15.6–27.2ROR 21.3 · χ² 874 / p 2e-192	20.4 EB05 16.0 · IC025 +3.6 3/3 methods agree	No label text to screen	–	no trial data cached
Ascites	38	20.5 15.0–28.1ROR 21.1 · χ² 686 / p 2e-151	20.3 EB05 15.4 · IC025 +3.5 3/3 methods agree	No label text to screen	–	no trial data cached
Malignant neoplasm progression	130	20.3 17.2–23.9ROR 22.4 · χ² 2,370 / p <1e-300	20.2 EB05 17.4 · IC025 +3.9 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Nephropathy toxic	14	20.0 11.9–33.6ROR 20.2 · χ² 233 / p 6e-53	19.2 EB05 11.8 · IC025 +2.7 3/3 methods agree	No label text to screen	–	no trial data cached
Electrocardiogram qt prolonged	39	17.2 12.6–23.4ROR 17.7 · χ² 580 / p 2e-128	17.0 EB05 12.9 · IC025 +3.3 3/3 methods agree	No label text to screen	–	no trial data cached
Drug-induced liver injury	25	12.9 8.7–19.0ROR 13.1 · χ² 262 / p 3e-59	12.3 EB05 8.4 · IC025 +2.7 3/3 methods agree	No label text to screen	–	no trial data cached
Aspartate aminotransferase increased	40	12.0 8.8–16.2ROR 12.3 · χ² 391 / p 2e-87	11.6 EB05 8.7 · IC025 +2.9 3/3 methods agree	Lab value / disease marker	–	no trial data cached
Therapy partial responder	11	11.6 6.4–20.9ROR 11.7 · χ² 96 / p 5e-23	9.7 EB05 5.2 · IC025 +2.0 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Alanine aminotransferase increased	40	10.3 7.6–14.0ROR 10.6 · χ² 329 / p 9e-74	9.9 EB05 7.4 · IC025 +2.7 3/3 methods agree	Lab value / disease marker	–	no trial data cached
Proteinuria	12	10.1 5.7–17.7ROR 10.2 · χ² 90 / p 2e-21	8.4 EB05 4.7 · IC025 +1.9 3/3 methods agree	No label text to screen	–	no trial data cached
Drug resistance	15	9.3 5.6–15.3ROR 9.4 · χ² 103 / p 2e-24	7.9 EB05 4.8 · IC025 +2.0 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Pericardial effusion	13	9.0 5.2–15.4ROR 9.0 · χ² 84 / p 2e-20	7.4 EB05 4.4 · IC025 +1.9 3/3 methods agree	No label text to screen	–	no trial data cached
Hypocalcaemia (low calcium)	10	8.4 4.5–15.6ROR 8.5 · χ² 58 / p 1e-14	6.6 EB05 3.7 · IC025 +1.6 3/3 methods agree	No label text to screen	–	no trial data cached
Hepatic failure	16	8.4 5.2–13.7ROR 8.5 · χ² 97 / p 3e-23	7.2 EB05 4.5 · IC025 +1.9 3/3 methods agree	No label text to screen	–	no trial data cached
Mucosal inflammation	11	6.7 3.7–12.1ROR 6.7 · χ² 48 / p 2e-12	5.4 EB05 3.2 · IC025 +1.4 3/3 methods agree	No label text to screen	–	no trial data cached
Myelosuppression	13	6.1 3.5–10.4ROR 6.1 · χ² 50 / p 7e-13	5.1 EB05 3.2 · IC025 +1.4 3/3 methods agree	No label text to screen	–	no trial data cached
Pneumonitis	10	5.9 3.2–10.9ROR 5.9 · χ² 36 / p 1e-9	4.7 EB05 2.8 · IC025 +1.2 3/3 methods agree	No label text to screen	–	no trial data cached
Therapy interrupted	22	5.1 3.3–7.7ROR 5.1 · χ² 68 / p 9e-17	4.6 EB05 3.2 · IC025 +1.5 3/3 methods agree	Reporting / coding artifact	–	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Malignant neoplasm progression	130	20.3 17.2–23.9ROR 22.4 · χ² 2,370 / p <1e-300	20.2 EB05 17.4 · IC025 +3.9 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Hepatic function abnormal	48	20.6 15.6–27.2ROR 21.3 · χ² 874 / p 2e-192	20.4 EB05 16.0 · IC025 +3.6 3/3 methods agree	No label text to screen	–	no trial data cached
Alanine aminotransferase increased	40	10.3 7.6–14.0ROR 10.6 · χ² 329 / p 9e-74	9.9 EB05 7.4 · IC025 +2.7 3/3 methods agree	Lab value / disease marker	–	no trial data cached
Aspartate aminotransferase increased	40	12.0 8.8–16.2ROR 12.3 · χ² 391 / p 2e-87	11.6 EB05 8.7 · IC025 +2.9 3/3 methods agree	Lab value / disease marker	–	no trial data cached
Electrocardiogram qt prolonged	39	17.2 12.6–23.4ROR 17.7 · χ² 580 / p 2e-128	17.0 EB05 12.9 · IC025 +3.3 3/3 methods agree	No label text to screen	–	no trial data cached
Ascites	38	20.5 15.0–28.1ROR 21.1 · χ² 686 / p 2e-151	20.3 EB05 15.4 · IC025 +3.5 3/3 methods agree	No label text to screen	–	no trial data cached
Hepatotoxicity (liver damage)	34	24.4 17.5–34.0ROR 25.0 · χ² 738 / p 7e-163	24.0 EB05 18.0 · IC025 +3.6 3/3 methods agree	No label text to screen	–	no trial data cached
Liver function test increased	29	21.6 15.1–31.0ROR 22.1 · χ² 549 / p 1e-121	21.3 EB05 15.5 · IC025 +3.4 3/3 methods agree	No label text to screen	–	no trial data cached
Drug-induced liver injury	25	12.9 8.7–19.0ROR 13.1 · χ² 262 / p 3e-59	12.3 EB05 8.4 · IC025 +2.7 3/3 methods agree	No label text to screen	–	no trial data cached
Therapy interrupted	22	5.1 3.3–7.7ROR 5.1 · χ² 68 / p 9e-17	4.6 EB05 3.2 · IC025 +1.5 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Hepatic cytolysis	17	22.1 13.8–35.4ROR 22.4 · χ² 321 / p 4e-72	21.5 EB05 14.1 · IC025 +3.0 3/3 methods agree	No label text to screen	–	no trial data cached
Hepatic failure	16	8.4 5.2–13.7ROR 8.5 · χ² 97 / p 3e-23	7.2 EB05 4.5 · IC025 +1.9 3/3 methods agree	No label text to screen	–	no trial data cached
Drug resistance	15	9.3 5.6–15.3ROR 9.4 · χ² 103 / p 2e-24	7.9 EB05 4.8 · IC025 +2.0 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Nephropathy toxic	14	20.0 11.9–33.6ROR 20.2 · χ² 233 / p 6e-53	19.2 EB05 11.8 · IC025 +2.7 3/3 methods agree	No label text to screen	–	no trial data cached
Myelosuppression	13	6.1 3.5–10.4ROR 6.1 · χ² 50 / p 7e-13	5.1 EB05 3.2 · IC025 +1.4 3/3 methods agree	No label text to screen	–	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Selpercatinib?

In FDA FAERS, the most frequently co-reported reaction terms for Selpercatinib are hepatic function abnormal, alanine aminotransferase increased, aspartate aminotransferase increased, electrocardiogram qt prolonged, ascites, hepatotoxicity. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Selpercatinib have an FDA boxed warning?

No validated FDA label could be retrieved for this product name, so this page cannot say.

Do FAERS signals prove that Selpercatinib causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

No FDA label passed the name-validation check for this product string, so label-based screening was skipped
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 30 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.